908601-49-0
908601-49-0
Chemical Structure
SB-616234-A
- CAS No.: 908601-49-0
- Formula:C32H36ClN5O3
- Molecular Weight:574.11
IUPAC Name: (6-((3R,5S)-3,5-dimethylpiperazin-1-yl)-5-methoxyindolin-1-yl)(2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)-[1,1'-biphenyl]-4-yl)methanone hydrochloride
InChIKey: VPWVEPYFVFBHQR-XKFLBXONSA-N
SMILES: O=C(N1CCC2=C1C=C(N3C[C@@H](C)N[C@@H](C)C3)C(OC)=C2)C4=CC=C(C5=CC=C(C6=NOC(C)=N6)C=C5C)C=C4.[H]Cl
Biological Activity: SB-616234-A is a selective and orally bioavailable 5-HT1B receptor antagonist, with anxiolytic and antidepressant activity.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SB-616234-A | 99.40% | SB-616234-A is a selective and orally bioavailable 5-HT1B receptor antagonist, with anxiolytic and antidepressant activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ML385 | 99.84% | ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GR127935 hydrochloride | 99.38% | GR127935 hydrochloride is a selective and orally active 5-HT1D and 5-HT1B receptor antagonist with pKi values of 8.5 for both receptors. GR127935 hydrochloride impairs memory acquisition and Serotonin (HY-B1473A)-mediated vasodilation. GR127935 hydrochloride can be used for research on amnesia, neuroendocrine cancer, and migraine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-224289 | SB-224289 is a selective 5-HT1B receptor antagonist, with anxiolytic effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-224289 hydrochloride | 99.0% | SB-224289 hydrochloride is a selective 5-HT1B receptor antagonist, with anxiolytic effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-216641A | 98.04% | SB-216641A (SB-216641 hydrochloride) is a selective antagonist of 5-HT1B/D receptor. SB-216641A shows high affinity and selectivity for h5-HT1B receptors over h5-HT1D receptors. SB-216641A inhibits the function of SKF-99101H. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-236057 | SB-236057 is an inverse agonist of the 5-HT1B receptor that exhibits strong skeletal teratogenicity in rodents and rabbits. SB-236057 affects gene expression during embryonic development through interference with the Notch signaling pathway and interaction with r-esp1. SB-236057 induces somatic patterning and tail extension defects in rat embryos during early organogenesis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GR 125743 | 99.77% | GR 125743 is a selective 5-HT1B/1D receptor antagonist, with pKis of 8.85 and 8.31 for wild-type h5-HT1B and wild-type h5-HT1D, respectively. GR 125743 is used for the research of Parkinson's disease and cardiovascular diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GR127935 | 99.33% | GR127935 is a selective and orally active 5-HT1D and 5-HT1B receptor antagonist with pKi values of 8.5 for both receptors. GR127935 impairs memory acquisition and Serotonin (HY-B1473A)-mediated vasodilation. GR127935 can be used for research on amnesia, neuroendocrine cancer, and migraine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HPK1-IN-9 | HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) . | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-216641 | SB-216641 is a selective 5-HT1b antagonist. SB-216641 mildly prevents stress-induced behavioral performance dysregulations. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
